New Cholesterol Guidelines Urge Earlier, More Personalized Heart Risk Checks

The American College of Cardiology and the American Heart Association have issued new clinical guidelines that could change how millions of people are assessed and treated for cardiovascular risk. The central message is that doctors should not wait until cholesterol is very high or the patient is older. Instead, they should identify risk as early as possible, tailor the evaluation to each person, and aim for lower LDL, the so-called bad cholesterol.

The recommendations, published in the societies’ scientific journals, are based on a large body of recent research showing that the lower LDL stays across a lifetime, the lower the risk of heart attack, stroke, and heart failure. The new approach broadens risk assessment beyond cholesterol, blood pressure, and age to include family history, inflammatory diseases such as rheumatoid arthritis, and women-specific conditions including preeclampsia, gestational diabetes, and early menopause. It also gives greater weight to lipoprotein(a), or Lp(a), and recommends testing it at least once in a lifetime. High levels may raise heart disease risk by about 40 percent, and even double it at very high levels.

Another major change is earlier screening. Children and adolescents suspected of familial hypercholesterolemia, a genetic disorder that causes very high LDL, should begin testing around age nine, and sometimes earlier. The authors say lowering cholesterol and blood pressure in the 20s and 30s can affect heart and artery health for life. The new PREVENT calculator is also intended to replace the older 10-year model, using data from about 6.6 million people instead of roughly 26,000, and projecting risk over 30 years while also factoring in blood sugar and kidney function.

Despite the new tools, the core prevention advice remains the same, balanced diet, regular exercise, no smoking, enough sleep, and a healthy weight. The guidelines estimate that 80 to 90 percent of heart disease is tied at least partly to modifiable risk factors. Treatment targets are tighter too, with LDL goals of under 100 mg/dL for people without known heart disease, under 70 for moderate risk, and under 55 for high risk. The document also discusses Non HDL cholesterol, apolipoprotein B, and additional drugs such as ezetimibe, bempedoic acid, and PCSK9 antibodies for patients who do not reach targets on statins alone.